Article: Risk Factors for Development of Paradoxical Response During Antituberculosis Therapy in HIV-Negative Patients

File Download Links for fulltext
(May Require Subscription)
Supplementary

  • Basic View
  • Metadata View
  • XML View
TitleRisk Factors for Development of Paradoxical Response During Antituberculosis Therapy in HIV-Negative Patients
AuthorsCheng, VCC1
Yam, WC1
Woo, PCY1
Lau, SKP1
Hung, IFN1
Wong, SPY1
Cheung, WC1
Yuen, KY1
KeywordsImmunocompromised Host
Bone Marrow Transplantation - immunology
Immunosuppressive Agents - administration & dosage
Lymphocyte Count
Issue Date2003
PublisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/10096/index.htm
CitationEuropean Journal Of Clinical Microbiology And Infectious Diseases, 2003, v. 22 n. 10, p. 597-602 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s10096-003-0998-z
AbstractThe risk factors for development of paradoxical response were studied in a cohort of 104 patients with culture-documented Mycobacterium tuberculosis infection. Paradoxical deterioration occurred in 16 (15.4%) patients (case group) during antituberculosis therapy, involving lungs and pleura (n=4), spine and paraspinal tissue (n=5), intracranium (n=3), peritoneum (n=2), bone and joint (n=1), and lymph node (n=1). The median time from commencement of treatment to paradoxical deterioration was 56 days (range, 20-109 days). Compared with 53 patients without clinical deterioration after antituberculosis therapy (control group), patients with paradoxical response were more likely to have extrapulmonary involvement (62.5% vs. 17.0%; P<0.05) at initial diagnosis, to have lower baseline lymphocyte counts (672±315 cells/μl vs. 1,328±467 cells/μl; P<0.001), and to exhibit a greater surge in lymphocyte counts (627±465 cells/μl vs. 225±216 cells/ μl; P<0.05) during paradoxical response. Further studies on lymphocyte subsets and cytokine levels would be useful in understanding the exact immunological mechanisms involved in immunorestitution.
ISSN0934-9723
2011 Impact Factor: 2.859
2011 SCImago Journal Rankings: 0.215
DOIhttp://dx.doi.org/10.1007/s10096-003-0998-z
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorCheng, VCC
dc.contributor.authorYam, WC
dc.contributor.authorWoo, PCY
dc.contributor.authorLau, SKP
dc.contributor.authorHung, IFN
dc.contributor.authorWong, SPY
dc.contributor.authorCheung, WC
dc.contributor.authorYuen, KY
dc.date.accessioned2008-05-22T04:19:50Z
dc.date.available2008-05-22T04:19:50Z
dc.date.issued2003
dc.description.abstractThe risk factors for development of paradoxical response were studied in a cohort of 104 patients with culture-documented Mycobacterium tuberculosis infection. Paradoxical deterioration occurred in 16 (15.4%) patients (case group) during antituberculosis therapy, involving lungs and pleura (n=4), spine and paraspinal tissue (n=5), intracranium (n=3), peritoneum (n=2), bone and joint (n=1), and lymph node (n=1). The median time from commencement of treatment to paradoxical deterioration was 56 days (range, 20-109 days). Compared with 53 patients without clinical deterioration after antituberculosis therapy (control group), patients with paradoxical response were more likely to have extrapulmonary involvement (62.5% vs. 17.0%; P<0.05) at initial diagnosis, to have lower baseline lymphocyte counts (672±315 cells/μl vs. 1,328±467 cells/μl; P<0.001), and to exhibit a greater surge in lymphocyte counts (627±465 cells/μl vs. 225±216 cells/ μl; P<0.05) during paradoxical response. Further studies on lymphocyte subsets and cytokine levels would be useful in understanding the exact immunological mechanisms involved in immunorestitution.
dc.description.naturepostprint
dc.format.extent122809 bytes
dc.format.extent1902 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.identifier.citationEuropean Journal Of Clinical Microbiology And Infectious Diseases, 2003, v. 22 n. 10, p. 597-602 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s10096-003-0998-z
dc.identifier.doihttp://dx.doi.org/10.1007/s10096-003-0998-z
dc.identifier.epage602
dc.identifier.hkuros87975
dc.identifier.isiWOS:000186035600004
dc.identifier.issn0934-9723
2011 Impact Factor: 2.859
2011 SCImago Journal Rankings: 0.215
dc.identifier.issue10
dc.identifier.openurl
dc.identifier.pmid14508660
dc.identifier.scopuseid_2-s2.0-0242329701
dc.identifier.spage597
dc.identifier.urihttp://hdl.handle.net/10722/48642
dc.identifier.volume22
dc.languageeng
dc.publisherSpringer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/10096/index.htm
dc.publisher.placeGermany
dc.relation.ispartofEuropean Journal of Clinical Microbiology and Infectious Diseases
dc.relation.referencesReferences in Scopus
dc.rightsThe original publication is available at www.springerlink.com
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
dc.subjectImmunocompromised Host
dc.subjectBone Marrow Transplantation - immunology
dc.subjectImmunosuppressive Agents - administration & dosage
dc.subjectLymphocyte Count
dc.titleRisk Factors for Development of Paradoxical Response During Antituberculosis Therapy in HIV-Negative Patients
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong